Enjoy complimentary customisation on priority with our Enterprise License!
The hemostats and tissue sealants market size is forecast to increase by USD 3.35 billion at a CAGR of 11.79% between 2023 and 2028. The market is witnessing significant growth due to the high usage of these products in surgeries for effective bleeding control and tissue repair. The increasing focus on research and development (R&D) to innovate novel hemostats and tissue sealants is another major market growth factor. However, the high cost of these products remains a significant challenge for the market. Despite the challenges, the market is expected to grow steadily due to the increasing number of surgical procedures and the need for efficient hemostats and tissue sealants to ensure optimal patient outcomes. The market is also driven by the rising prevalence of chronic diseases and injuries, leading to an increased demand for surgical interventions and associated hemostats and tissue sealants.
The market is witnessing significant growth due to the increasing number of surgical procedures, particularly in the areas of geriatric population, chronic conditions, critical care, and slow-healing injuries. Bleeding and hemorrhage are common complications during surgeries, and hemostats and tissue sealants play a crucial role in controlling blood loss and promoting tissue healing. Factors such as diabetes, cancer, cardiovascular diseases, hernia fixation, spinal injuries, ophthalmic injuries, urological disorders, burns, minimally invasive surgeries, neurological diseases, and coagulation system disorders are driving the demand for hemostats and tissue sealants. Fibrin sealant products, topical hemostats, adhesives, and energy-based devices are the major types of hemostats and tissue sealants.
Furthermore, reimbursements and regulations are key factors influencing the market's growth. However, the lack of reimbursements and adverse reactions to hemostats and tissue sealants may pose challenges to market growth. Healthcare professionals prefer hemostats and tissue sealants due to their global presence and effectiveness in controlling bleeding. European approval and product substitutes such as sutures and staples are also impacting the market dynamics.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The hemostats segment is estimated to witness significant growth during the forecast period. Hemostats and tissue sealants are essential surgical products used to manage bleeding and prevent hemorrhage during injuries and surgical procedures. These medical devices are particularly crucial for older patients and those suffering from chronic conditions, such as diabetes, cancer, cardiovascular diseases, neurological diseases, and urological disorders. The American population, with its increasing geriatric population and prevalence of chronic diseases, presents a significant market opportunity for hemostats and tissue sealants. Mechanical hemostats, made from materials like gelatin, collagen, cellulose, and polysaccharides, act as physical barriers to stop blood flow. Examples include GELFOAM Sterile Sponge from Pfizer and SURGICEL Original Absorbable Hemostat from Johnson & Johnson Services.
Furthermore, active hemostats and flowable hemostats, which contain thrombin or other active biological compounds, also play a vital role in achieving hemostasis. In critical care settings, hemostats and tissue sealants are crucial for managing slow-healing injuries, complications from minimally invasive surgeries, and severe wounds. However, the lack of reimbursements and potential adverse reactions can pose challenges to the market growth. The market for hemostats and tissue sealants is concentrated, with key players like Ethicon and Johnson & Johnson having a global presence. Despite these challenges, the demand for these products remains high due to their critical role in various surgical procedures, including cardiovascular surgeries, hernia fixation, spinal injuries, ophthalmic injuries, and urology.
Get a glance at the market share of various segments Request Free Sample
The Hemostats segment was valued at USD 2.07 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The European market encompasses a range of products used to control bleeding during surgical procedures. These include mechanical hemostats, flowable hemostats, active hemostats, and adhesion barrier products. Terumo Corporation, a leading player in this market, has received European approval for its AQUABRID product, a gelatin-based topical hemostat. Regulations governing the use of these products are stringent, with a focus on ensuring patient safety and efficacy. Sutures and staples are traditional methods for hemostasis, but energy-based devices, fibrin sealant products, and synthetic or natural tissue sealants are gaining popularity. General surgery, hospitals, and specialty clinics are key end-users. Coagulation system disorders, such as hemophilia and immune thrombocytopenia, necessitate the use of specialized hemostats and tissue sealants.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high use of hemostats and tissue sealants in surgeries is the key driver of the market. Every month, approximately 25 million surgical procedures are carried out globally, with a considerable number of these procedures encountering complications such as bleeding and the leakage of bodily fluids. Such adverse events can lead to serious clinical consequences, including hemodynamic instability, hypovolemia, anemia, and a heightened risk of organ failure. Injuries and surgical procedures among older patients, those with chronic conditions like diabetes, cancer, cardiovascular diseases, and neurological or urological disorders, are particularly susceptible to these complications. Hemostats and tissue sealants have emerged as essential surgical products in addressing these challenges. By facilitating hemostasis, hemostats help minimize blood loss during surgeries, ensuring optimal oxygen delivery to vital tissues.
Furthermore, tissue-sealing agents prevent leakages from suture lines, thereby reducing the risk of complications and the need for re-interventions. Compared to traditional methods like sutures and wires, hemostats and tissue sealants offer several advantages. They expedite the process of achieving hemostasis, inflict less pain on patients, and do not necessitate removal. These benefits are particularly crucial in critical care settings, such as cardiovascular surgeries and trauma cases, where rapid hemostasis and minimal tissue damage are essential. Despite their proven benefits, the adoption of hemostats and tissue sealants is not without challenges. Lack of reimbursements and adverse reactions, including complications, can hinder market growth.
Moreover, the market for hemostats and tissue sealants is currently concentrated, with key players holding a significant share. The global presence of these companies enables them to cater to diverse patient populations, including those with chronic diseases like diabetes, cancer, and cardiovascular diseases, as well as injuries ranging from spinal and ophthalmic to urological and burns. However, ongoing research and development efforts aim to improve the safety and efficacy of these products, ensuring their continued relevance in minimally invasive surgeries and various medical specialties, including urology, neurology, and cardiology.
The increasing R and D focus on novel hemostats and tissue sealants is the upcoming trend in the market. The market is witnessing significant growth due to the increasing prevalence of bleeding and hemorrhage during surgical procedures and injuries in the geriatric population and those suffering from chronic conditions such as diabetes, cancer, cardiovascular diseases, neurological diseases, and urological disorders. In the American population, the increasing number of critical care patients and older patients with slow-healing injuries require advanced surgical products for effective hemostasis and tissue sealing. Baxter International and 3-D Matrix Medical Technology are among the companies investing in research and development to address this need. Baxter launched next-generation hemostats and sealants with advanced delivery systems and expanded indications for its tissue sealants.
Furthermore, meanwhile, 3-D Matrix is developing a synthetic hemostatic material called PuraStat, the first hemostatic agent indicated to reduce delayed bleeding following gastrointestinal endoscopic submucosal dissection procedures. Despite the market's potential, lack of reimbursements and adverse reactions or complications pose challenges. Market concentration is high, with key players such as Ethicon, a Johnson & Johnson company, dominating the landscape. Healthcare professionals seek global presence and innovative solutions from these companies to meet the diverse needs of patients in various specialties, including cardiovascular surgeries, urology, and ophthalmology.
The high cost of hemostats and tissue sealants is a key challenge affecting the market growth. The market faces growth constraints due to the high cost of advanced hemostats and tissue sealants. For instance, the per-unit cost of fibrin sealants ranges from USD50 to USD600, mechanical hemostats from USD 50 to USD 200, and active flowable from USD 200 to USD 300. The use of these products varies depending on the nature of injuries and surgical procedures, with older patients and those suffering from chronic conditions, such as diabetes, cancer, cardiovascular diseases, neurological diseases, and urological disorders, being frequent users. In critical care settings, where hemorrhage is a significant concern, hemostats and tissue sealants play a crucial role in managing bleeding and promoting wound healing.
However, the high cost and lack of reimbursements in several geographies, particularly developing economies, limit their widespread adoption. Moreover, adverse reactions and complications associated with these products can lead to additional healthcare expenses. Despite these challenges, the market for hemostats and tissue sealants is expected to grow due to the increasing prevalence of injuries and chronic diseases, the rising number of minimally invasive surgeries, and the global presence of key players such as Ethicon, a Johnson & Johnson company.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Advanced Medical Solutions Group Plc - The company offers hemostats and tissue sealants under the brands, such as LiquiBand and ActivHeal.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The global market is expected to experience significant growth due to the increasing prevalence of bleeding and hemorrhage during injuries and surgical procedures. The geriatric population and those with chronic conditions, such as diabetes, cancer, and cardiovascular diseases, are at a higher risk of experiencing slow-healing injuries and chronic disease-related complications. In critical care settings, older patients undergoing surgeries for conditions like hernia fixation, spinal injuries, ophthalmic injuries, and urological disorders require effective hemostats and tissue sealants to prevent bleeding and minimize complications. The market for hemostats and tissue sealants is driven by the growing number of minimally invasive surgeries, particularly in urology, and the need for reimbursements for surgical products.
However, the lack of reimbursements and adverse reactions to hemostats and tissue-sealing agents may pose challenges to market growth. The market is concentrated with key players having a global presence, including Ethicon, a Johnson & Johnson company. Healthcare professionals continue to seek advanced and effective hemostats and tissue sealants to address the complex needs of patients undergoing various surgical procedures.
Market Scope |
|
Report Coverage |
Details |
Page number |
177 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 11.79% |
Market growth 2024-2028 |
USD 3.35 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
10.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, Germany, UK, Canada, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Advanced Medical Solutions Group Plc, B.Braun SE, Baxter International Inc., Becton Dickinson and Co., BioCer Entwicklungs GmbH, Cardinal Health Inc., CSL Ltd., CuraMedical BV, Hemostasis LLC, Integra Lifesciences Corp., Johnson and Johnson Services Inc., KATSAN KATGUT SANAYI VE TICARET A.S, Medtronic Plc, Pfizer Inc., Smith and Nephew plc, Stryker Corp., Teijin Ltd., Teleflex Inc., Tricol Biomedical Inc., and Vivostat AS |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.